Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ERNA Eterna Therapeutics Inc
- Stocks
- Healthcare
- NYSEAMERICAN: ERNA
Price (delayed)
$1.81
Market cap
$7.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$32.7
Enterprise value
$8.49M
Highlights
The gross margin has soared by 181% YoY and by 12% from the previous quarter
The debt has shrunk by 94% YoY
Eterna Therapeutics's net income has plunged by 101% YoY and by 3.5% from the previous quarter
The quick ratio has plunged by 84% YoY and by 73% from the previous quarter
Key stats
What are the main financial stats of ERNA
Market
Valuations
Earnings
Shares outstanding
4.16M
Market cap
$7.53M
Enterprise value
$8.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
12.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.87
Revenue
$535,000
Gross profit
$500,000
Operating income
-$14.33M
Net income
-$46.09M
EBIT
-$40.1M
EBITDA
-$38.93M
Free cash flow
-$14.42M
Per share
Balance sheet
Liquidity
EPS
-$32.7
EPS diluted
-$32.7
Free cash flow per share
-$4.05
Book value per share
-$1.71
Revenue per share
$0.15
TBVPS
$0.85
Total assets
$5.06M
Total liabilities
$11.01M
Debt
$2.88M
Equity
-$5.95M
Working capital
-$8.23M
Debt to equity
-0.48
Current ratio
0.21
Quick ratio
0.2
Net debt/EBITDA
-0.02
Margins
Efficiency
Dividend
EBITDA margin
-7,277.2%
Gross margin
93.5%
Net margin
-8,615.7%
Operating margin
-2,678.1%
Return on assets
-285.8%
Return on equity
N/A
Return on invested capital
-160.3%
Return on capital employed
N/A
Return on sales
-7,495.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ERNA stock price
How has the Eterna Therapeutics stock price performed over time
Intraday
-2.16%
1 week
-24.58%
1 month
-44.65%
1 year
-93.41%
YTD
-58.96%
QTD
-32.21%
Financial performance
How have Eterna Therapeutics's revenue and profit performed over time
Revenue
$535,000
Gross profit
$500,000
Operating income
-$14.33M
Net income
-$46.09M
Gross margin
93.5%
Net margin
-8,615.7%
The gross margin has soared by 181% YoY and by 12% from the previous quarter
Eterna Therapeutics's net income has plunged by 101% YoY and by 3.5% from the previous quarter
ERNA's operating margin has surged by 86% year-on-year and by 10% since the previous quarter
The net margin has soared by 57% YoY but it is down by 13% QoQ
Price vs fundamentals
How does ERNA's price correlate with its fundamentals
Growth
What is Eterna Therapeutics's growth rate over time
Valuation
What is Eterna Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
12.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.87
Eterna Therapeutics's EPS has increased by 49% YoY and by 33% from the previous quarter
ERNA's equity has dropped by 74% year-on-year
The P/S is 48% lower than the last 4 quarters average of 23.8
The company's revenue fell by 8% QoQ
Efficiency
How efficient is Eterna Therapeutics business performance
The company's return on invested capital has shrunk by 96% QoQ
The ROA has plunged by 75% from the previous quarter
Eterna Therapeutics's ROS has soared by 60% YoY but it has decreased by 16% from the previous quarter
Dividends
What is ERNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ERNA.
Financial health
How did Eterna Therapeutics financials performed over time
Eterna Therapeutics's total assets is 54% lower than its total liabilities
Eterna Therapeutics's total assets has shrunk by 90% YoY and by 4% QoQ
The quick ratio has plunged by 84% YoY and by 73% from the previous quarter
The debt is 148% higher than the equity
The debt to equity has soared by 97% YoY
The debt has shrunk by 94% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.